Flubromazolam’s position in clinical trials is limited because of its classification for a designer drug. However, its consequences are actually reversed by the benzodiazepine antagonist flumazenil in pharmacokinetic studies, giving insights into its clinical implications and unexpected emergency administration of overdoses.Nitrates are also loc

Article Under Review